TY - JOUR
T1 - Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases
AU - Soós, Boglárka
AU - Szentpétery, Ágnes
AU - Raterman, Hennie G.
AU - Lems, Willem F.
AU - Bhattoa, Harjit P.
AU - Szekanecz, Zoltán
N1 - Funding Information: The authors’ work is supported by Hungarian National Scientific Research Fund (OTKA) grant No. K 105073 (to H.P.B. and Z.S.); the TÁMOP-4.2.4.A/2-11-1-2012-0001 National Excellence Program co-financed by the European Union and Hungary (to Z.S.) and the European Union G INOP-2.3.2-15-2016-00050 grant (to Z.S.). Publisher Copyright: © 2022, Springer Nature Limited.
PY - 2022/5
Y1 - 2022/5
N2 - Generalized bone loss (osteoporosis) and fragility fractures can occur in rheumatic and musculoskeletal diseases including rheumatoid arthritis and spondyloarthritis (SpA; including ankylosing spondylitis and psoriatic arthritis). In addition, rheumatoid arthritis can involve localized, periarticular bone erosion and, in SpA, local (pathological) bone formation can occur. The RANK–RANKL–osteoprotegerin axis and the Wnt–β-catenin signalling pathway (along with its inhibitors sclerostin and Dickkopf 1) have been implicated in inflammatory bone loss and formation, respectively. Targeted therapies including biologic DMARDs and Janus kinase (JAK) inhibitors can stabilize bone turnover and inhibit radiographic joint damage, and potentially also prevent generalized bone loss. Targeted therapies interfere at various points in the mechanisms of local and generalized bone changes in systemic rheumatic diseases, and they effect biomarkers of bone resorption and formation, bone mass and risk of fragility fractures. Studies on the effects of targeted therapies on rates of fragility fracture are scarce. The efficacy of biologic DMARDs for arresting bone formation in axial SpA is debated. Improved understanding of the most relevant therapeutic targets and identification of important targeted therapies could lead to the preservation of bone in inflammatory rheumatic and musculoskeletal diseases.
AB - Generalized bone loss (osteoporosis) and fragility fractures can occur in rheumatic and musculoskeletal diseases including rheumatoid arthritis and spondyloarthritis (SpA; including ankylosing spondylitis and psoriatic arthritis). In addition, rheumatoid arthritis can involve localized, periarticular bone erosion and, in SpA, local (pathological) bone formation can occur. The RANK–RANKL–osteoprotegerin axis and the Wnt–β-catenin signalling pathway (along with its inhibitors sclerostin and Dickkopf 1) have been implicated in inflammatory bone loss and formation, respectively. Targeted therapies including biologic DMARDs and Janus kinase (JAK) inhibitors can stabilize bone turnover and inhibit radiographic joint damage, and potentially also prevent generalized bone loss. Targeted therapies interfere at various points in the mechanisms of local and generalized bone changes in systemic rheumatic diseases, and they effect biomarkers of bone resorption and formation, bone mass and risk of fragility fractures. Studies on the effects of targeted therapies on rates of fragility fracture are scarce. The efficacy of biologic DMARDs for arresting bone formation in axial SpA is debated. Improved understanding of the most relevant therapeutic targets and identification of important targeted therapies could lead to the preservation of bone in inflammatory rheumatic and musculoskeletal diseases.
UR - http://www.scopus.com/inward/record.url?scp=85126002355&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41584-022-00764-w
DO - https://doi.org/10.1038/s41584-022-00764-w
M3 - Review article
C2 - 35273387
SN - 1759-4790
VL - 18
SP - 249
EP - 257
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 5
ER -